BACKGROUND: The kinesin spindle protein Eg5 is involved in mitosis, and its inhibition promotes mitotic arrest. EMD 534085, a potent, reversible Eg5 inhibitor, demonstrated significant preclinical antitumor activity. METHODS: This first-in-man, single-center, open-label, phase I dose-escalation study (3 + 3 design) investigated EMD 534085 safety, pharmacokinetics and antitumor activity in refractory solid tumors, Hodgkin's lymphoma, or non-Hodgkin's lymphoma. EMD 534085 (starting dose 2 mg/m²/day) was administered intravenously every 3 weeks. Doses were escalated in 100% steps in successive cohorts of 3 patients until grade 2 toxicity occurred, followed by 50% until the first dose-limiting toxicity (DLT) arose. If <2 of 6 patients experienced a DLT, doses were further increased by 25%. Dose-escalation was stopped if a DLT occurred in ≥2 of 6 patients. RESULTS: Forty-four patients received EMD 534085. Median treatment duration was 43 days (range, 21-337). Thirty-eight patients (86%) received ≥2 cycles. DLTs were grade 4 neutropenia (1 patient each at 108 and 135 mg/m²/day), and grade 3 acute coronary syndrome with troponin I elevation (1 patient at 135 mg/m²/day). The maximum tolerated dose (MTD) was 108 mg/m²/day. The most common treatment-related adverse events were asthenia (50%) and neutropenia (32%). EMD 534085 appeared to have linear pharmacokinetics. Increase in phospho-histone H3 positive cells in paired pre- and on-treatment biopsies showed evidence of target modulation. No complete or partial responses were observed. Best response was stable disease in 23 patients (52%). CONCLUSIONS: EMD 534085 appeared to be well tolerated; MTD was 108 mg/m²/day. Preliminary antitumor results suggested limited activity in monotherapy.
BACKGROUND: The kinesin spindle protein Eg5 is involved in mitosis, and its inhibition promotes mitotic arrest. EMD 534085, a potent, reversible Eg5 inhibitor, demonstrated significant preclinical antitumor activity. METHODS: This first-in-man, single-center, open-label, phase I dose-escalation study (3 + 3 design) investigated EMD 534085 safety, pharmacokinetics and antitumor activity in refractory solid tumors, Hodgkin's lymphoma, or non-Hodgkin's lymphoma. EMD 534085 (starting dose 2 mg/m²/day) was administered intravenously every 3 weeks. Doses were escalated in 100% steps in successive cohorts of 3 patients until grade 2 toxicity occurred, followed by 50% until the first dose-limiting toxicity (DLT) arose. If <2 of 6 patients experienced a DLT, doses were further increased by 25%. Dose-escalation was stopped if a DLT occurred in ≥2 of 6 patients. RESULTS: Forty-four patients received EMD 534085. Median treatment duration was 43 days (range, 21-337). Thirty-eight patients (86%) received ≥2 cycles. DLTs were grade 4 neutropenia (1 patient each at 108 and 135 mg/m²/day), and grade 3 acute coronary syndrome with troponin I elevation (1 patient at 135 mg/m²/day). The maximum tolerated dose (MTD) was 108 mg/m²/day. The most common treatment-related adverse events were asthenia (50%) and neutropenia (32%). EMD 534085 appeared to have linear pharmacokinetics. Increase in phospho-histone H3 positive cells in paired pre- and on-treatment biopsies showed evidence of target modulation. No complete or partial responses were observed. Best response was stable disease in 23 patients (52%). CONCLUSIONS: EMD 534085 appeared to be well tolerated; MTD was 108 mg/m²/day. Preliminary antitumor results suggested limited activity in monotherapy.
Authors: Kyle Holen; Robert DiPaola; Glenn Liu; Antoinette R Tan; George Wilding; Karl Hsu; Nancy Agrawal; Cong Chen; Lingling Xue; Elizabeth Rosenberg; Mark Stein Journal: Invest New Drugs Date: 2011-03-22 Impact factor: 3.850
Authors: Kyle D Holen; Chandra P Belani; George Wilding; Suresh Ramalingam; Jennifer L Volkman; Ramesh K Ramanathan; Lakshmi S Vasist; Carolyn J Bowen; Jeffrey P Hodge; Mohammed M Dar; Peter T C Ho Journal: Cancer Chemother Pharmacol Date: 2010-05-12 Impact factor: 3.333
Authors: Jared C Cochran; Christopher A Sontag; Zoltan Maliga; Tarun M Kapoor; John J Correia; Susan P Gilbert Journal: J Biol Chem Date: 2004-07-06 Impact factor: 5.157
Authors: Christopher W Lee; Karl Bélanger; Sanjay C Rao; Teresa M Petrella; Richard G Tozer; Lori Wood; Kerry J Savage; Elizabeth A Eisenhauer; Timothy W Synold; Nancy Wainman; Lesley Seymour Journal: Invest New Drugs Date: 2007-10-26 Impact factor: 3.850
Authors: Jennifer J Knox; Sharlene Gill; Timothy W Synold; James J Biagi; Pierre Major; Ron Feld; Christine Cripps; Nancy Wainman; Elizabeth Eisenhauer; Lesley Seymour Journal: Invest New Drugs Date: 2008-01-15 Impact factor: 3.850
Authors: Anna C Impastato; Andrej Shemet; Nynke A Vepřek; Gadiel Saper; Henry Hess; Lu Rao; Arne Gennerich; Dirk Trauner Journal: Angew Chem Int Ed Engl Date: 2022-01-14 Impact factor: 16.823